Reversible elevation of creatine kinase and creatinine caused by sintilimab-induced hypothyroidism: A case report.

ABSTRACT:

Rationale

Programmed cell death (PD) -1 inhibitors has significantly improved the prognosis of cancer patients by enhancing antitumor immune responses. However, PD-1 inhibitors are associated with immune-related adverse events, some of which are rare and potentially life-threatening. Thus far, elevated creatine kinase (CK) and creatinine caused by a novel PD-1 inhibitor (sintilimab)-induced hypothyroidism has not yet been reported.

Patient concerns

A 63-year-old male patient with esophageal cancer who developed hypothyroidism accompanied by unexplained increases in CK and creatinine after sintilimab treatment.

Diagnosis

Since the increases in CK and creatinine paralleled the decrease in thyroxine, after excluding other potential conditions, we speculated that the musc

SUBMITTER: Liu SR 

PROVIDER: S-EPMC11495781 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature